Applications of Quantum Computing in Drug Design and Molecular Simulation

Vanitha Devi Rajendran, Bavanishri Swaminathan, Souljer George Washington, Arivazhagan Dhandapani, Vinoth Jeevanesan*

Sir Issac Newton College of Pharmacy, Nagapattinam Tamil Nadu - 611 102, India
*Corresponding author: vinoth.sincop@gmail.com

Abstract

Drug discovery is a complex and computation-intensive process that traditionally relies on classical computing tools such as molecular docking and dynamics to simulate biological systems. However, these classical approaches struggle with accurately modelling quantum-level molecular phenomena, particularly electron correlation, transition states and non-covalent interactions. Quantum computing offers a revolutionary paradigm shift by leveraging the principles of quantum mechanics to simulate molecular systems with greater precision and scalability. Utilizing qubits that can exist in superposition and entanglement, quantum computers are uniquely suited for solving the Schrödinger equation and modelling molecular interactions at an atomic level. This review explores recent advancements in applying quantum computing to drug modelling, including contributions from IBM, SandboxAQ and Google Quantum AI. We also examine emerging quantum algorithms, hybrid quantum-classical systems and real-world applications in virtual screening, protein-ligand binding and ADMET prediction. While still in its infancy, quantum computing holds enormous potential to accelerate and enhance the efficiency, accuracy and cost-effectiveness of pharmaceutical R&D.

Keywords: *Quantum computing, Drug modelling, Quantum molecular simulation, QML, Schrödinger equation, Molecular docking, Drug discovery*

Introduction

The discovery and development of new drugs is a time-consuming, costly and complex undertaking. It involves multiple stages, from target identification and lead optimization to preclinical testing and regulatory approval. For decades, pharmaceutical researchers have relied on classical computing to model biological systems, predict drug-target interactions and perform virtual screening. Methods such as molecular docking, molecular dynamics (MD) and pharmacophore modelling have provided essential insights into the structural and functional properties of biomolecules. However, these techniques rely on approximations that often oversimplify molecular behaviour, especially at the quantum level where electron correlation, tunnelling and orbital hybridization play crucial roles.[1]

This inherent limitation reduces the accuracy and reliability of predictions, particularly for large, flexible or electronically complex systems.

Quantum computing introduces a fundamentally new way to process and simulate information, grounded in the principles of quantum mechanics. Unlike classical bits that exist in binary states (0 or 1), quantum bits—or qubits—can exist in a superposition of states and exhibit entanglement, enabling quantum computers to perform calculations in parallel and process exponentially larger datasets.[2] This capability makes them particularly well-suited for modelling quantum systems such as chemical reactions, protein-ligand interactions and molecular binding energies. Quantum computing allows for more accurate solutions to the Schrödinger equation, which governs the behaviour of atomic and molecular systems. By simulating these phenomena directly, quantum computers offer a level of precision that is unattainable with traditional computational approaches.[3]

In recent years, major advances have been made in this emerging field. Companies such as IBM, Google Quantum AI and SandboxAQ have developed quantum frameworks and tools for molecular simulation. IBM's Qiskit Chemistry module, for example, allows researchers to model small molecules using variational quantum algorithms.[4] SandboxAQ, a Google-Alphabet spin-off, has created a platform that integrates AI and quantum computing to facilitate faster and more accurate drug discovery. Their release of a 5.2 million compound 3D molecular dataset is helping to train quantum-ready AI models.[5] Google's Quantum AI division, in collaboration with AlphaFold, is exploring the application of quantum neural networks to enhance protein structure prediction.[6]

Although quantum hardware today remains in the Noisy Intermediate-Scale Quantum (NISQ) era, characterized by noisy qubits, limited coherence times and small qubit counts, hybrid quantum-classical models are already being employed to simulate biologically relevant systems.[7] These integrated approaches aim to mitigate the current limitations of quantum hardware while capitalizing on its advantages. In the coming years, as quantum systems scale and error correction improve, the pharmaceutical industry is likely to witness a significant transformation in how drugs are discovered and developed. This review provides a comprehensive overview of the role of quantum computing in drug modelling and molecular simulation, highlighting current technologies, applications and future directions that signal a paradigm shift in pharmaceutical innovation.

Classical Computational Limitations and the Quantum Advantage

The use of computational methods in drug discovery has revolutionized the efficiency, accuracy and scalability of lead identification, optimization and screening processes.[8] Classical tools such as molecular docking, molecular dynamics (MD) and quantitative structure-activity relationship (QSAR) models have long served as workhorses in computational pharmacology. These methods help reduce the dependency on resource-intensive experimental procedures by offering predictive insights into drug-target interactions and pharmacokinetic behaviours. Molecular docking simulates the interaction between a

ligand and a target receptor by predicting the best-fit binding conformation and estimating binding affinity. Similarly, MD simulates the movement of atoms and molecules over time, providing a dynamic view of biomolecular interactions under various physiological conditions.[9]

Despite their utility, these classical approaches come with critical limitations. Molecular docking often assumes rigidity in molecular structures and employs simplified scoring functions that fail to capture intricate quantum mechanical phenomena such as electron delocalization, hydrogen bonding fluctuations and polarization effects. MD, while dynamic, is constrained by the classical approximation of atomic forces through empirical force fields, which may not accurately reflect quantum mechanical changes in electronic configurations during biochemical reactions. These approximations hinder the ability to simulate transition states, intermediate species and chemical reactions with high fidelity.[10]

Quantum computing, on the other hand, provides a transformative approach by directly incorporating the fundamental laws of quantum mechanics into computational frameworks. Quantum bits (qubits) allow parallel computation through superposition and entanglement, enabling the simulation of complex molecular systems that are infeasible for classical computers. Algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Approximate Optimization Algorithm (QAOA) are particularly suitable for calculating molecular ground state energies and solving combinatorial optimization problems central to drug discovery.[11]

Furthermore, the integration of Quantum Machine Learning (QML) techniques is expanding the horizons of pharmaceutical data analysis. QML models offer the potential to outperform classical counterparts in pattern recognition, dimensionality reduction and classification tasks. For instance, quantum-enhanced support vector machines, kernel methods and quantum neural networks can be employed to predict molecular bioactivity, toxicity profiles and metabolic pathways with improved accuracy and reduced computational cost. These models exploit high-dimensional Hilbert spaces and quantum entanglement to capture subtle molecular features often lost in classical representations.[12]

The advent of quantum computing thus marks a paradigm shift, offering a more natural and scalable method for simulating quantum systems integral to drug design. Although the technology remains in the NISQ (Noisy Intermediate-Scale Quantum) phase, ongoing developments in quantum hardware, noise reduction techniques and hybrid quantum-classical algorithms are bridging the gap between theoretical potential and practical implementation. As quantum computing matures, its integration into the pharmaceutical domain is poised to significantly advance the scope and efficacy of computational drug discovery.

Current Industry Applications and Collaborative Initiatives

The growing interest in quantum computing's role in drug discovery has led to several notable collaborations between technology firms, pharmaceutical companies and academic institutions. These partnerships aim to explore the real-world application of quantum algorithms in medicinal chemistry, pharmacokinetics and molecular simulations.

IBM has been a pioneer in this domain through its open-source Qiskit framework, particularly the Qiskit Chemistry module. This tool enables the simulation of small molecular systems on quantum devices using algorithms like the Variational Quantum Eigensolver (VQE) and Unitary Coupled Cluster (UCC). Early demonstrations have involved modelling simple molecules such as LiH, BeH_2 and H_2O, establishing foundational proof-of-concept experiments that validate the feasibility of quantum simulations.[13] IBM is working with several pharmaceutical firms to scale these methods to more complex, drug-like molecules, focusing on improving binding affinity predictions and energy minimization strategies.[14]

SandboxAQ, an Alphabet spin-off, has developed an AI + Quantum (AQ) hybrid platform specifically designed for pharmaceutical R&D. One of its significant contributions includes the release of a 5.2 million 3D molecule dataset optimized for quantum simulation and machine learning integration. This dataset facilitates virtual screening processes and assists in training quantum-ready AI models capable of molecular docking and property prediction. SandboxAQ’s infrastructure is also being used to evaluate the feasibility of quantum-enhanced hit identification, an area of intense interest among drug developers seeking to shorten the discovery pipeline.[15]

ProteinQure, a Toronto-based biotechnology company, has made significant strides in peptide-based drug discovery using quantum annealing. By leveraging quantum hardware from D-Wave Systems, ProteinQure can simulate the electronic configurations of peptide-protein complexes, enabling more accurate predictions of binding conformations and energetic stability. These simulations are particularly relevant in oncology and autoimmune diseases, where peptide therapeutics are gaining traction for their specificity and minimal off-target effects.[16]

Google Quantum AI, in collaboration with DeepMind’s AlphaFold project, is investigating the potential of quantum neural networks to enhance protein structure prediction. While AlphaFold has already revolutionized protein folding using classical deep learning, integrating quantum computing is expected to refine predictions related to protein dynamics and ligand-binding site analysis. This research holds promise for enabling more precise structure-based drug design.[17]

Another prominent example is the collaboration between Classiq and Biogen. This initiative focuses on constructing custom quantum circuits for modelling neurological diseases, particularly Alzheimer's. Their joint efforts aim to simulate the molecular mechanisms underlying amyloid-beta plaque formation and tau protein aggregation using

quantum-enhanced algorithms. Such simulations could guide the design of small-molecule inhibitors capable of disrupting these pathological pathways.[18]

`These industry initiatives underscore a shared vision of leveraging quantum computing to redefine the frontiers of drug discovery. Although most projects are still exploratory, the momentum in collaborative innovation suggests that practical, quantum-augmented drug design solutions may emerge sooner than anticipated.

Emerging Quantum Applications in Pharmaceutical Modelling

Quantum computing is beginning to impact several stages of the pharmaceutical development pipeline, offering new capabilities for simulating complex molecular phenomena that are critical for drug efficacy and safety. One of the most promising applications lies in quantum-enhanced molecular simulations. Unlike classical models, which approximate molecular energies using empirical potentials, quantum algorithms can compute these energies from first principles. This allows for a more accurate estimation of electronic structures, transition states and reaction pathways that influence molecular reactivity, stability and selectivity.

For example, quantum algorithms such as the Variational Quantum Eigensolver (VQE) can model ground state energies with significantly improved precision. These calculations are fundamental in understanding how drug molecules interact with their biological targets at an atomic level, including the subtle changes in charge distribution and orbital overlap that determine binding affinity and specificity.[19] Quantum phase estimation (QPE), though more resource-intensive, is also being explored for its ability to offer exact energy eigenvalues of small- to medium-sized molecules.[20]

Another emerging application is quantum-enhanced molecular docking. Traditional docking tools often rely on scoring functions that neglect dynamic electrostatic interactions and quantum tunnelling effects, leading to false positives or negatives. Quantum computing provides a means to incorporate these effects, offering a more nuanced and realistic simulation of how ligands interact with flexible protein targets. Hybrid quantum-classical algorithms are now being tested to accelerate conformational sampling and improve scoring accuracy in virtual screening campaigns.

Quantum computing is also finding use in predictive toxicology and pharmacokinetics. Quantum machine learning (QML) models are capable of learning complex, nonlinear relationships in high-dimensional molecular descriptor spaces, enabling better predictions of ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties. These models use quantum-enhanced feature mapping and kernel methods to identify patterns that are often imperceptible to classical algorithms, potentially reducing late-stage drug failure due to unforeseen toxicity or poor bioavailability.[20]

Furthermore, *de novo* drug design is being revolutionized by quantum generative models. Techniques such as quantum Boltzmann machines and variational autoencoders can be adapted to generate novel molecular structures with desired physicochemical properties. These approaches allow researchers to explore larger chemical spaces and identify unique scaffolds that may have been overlooked using classical combinatorial libraries.[21]

The use of quantum-enhanced clustering and dimensionality reduction techniques is also transforming how compound libraries are analysed. Quantum k-means algorithms and quantum principal component analysis (qPCA) can uncover hidden substructures and relationships between compounds, aiding in scaffold hopping, lead optimization and target class identification.[22] Such analytical capabilities are especially useful when working with ultra-large chemical libraries or multi-target compounds.

Overall, the emerging applications of quantum computing in pharmaceutical modelling offer a dramatic improvement in precision, predictive capability and computational efficiency. As quantum hardware continues to evolve, these tools will become increasingly viable for routine use in drug discovery and development workflows.

Technical Barriers and Practical Constraints

Despite the remarkable potential of quantum computing in transforming pharmaceutical modelling, the field is currently constrained by several technical and practical challenges. Foremost among these is the immaturity of quantum hardware. Present-day quantum computers operate in what is known as the Noisy Intermediate-Scale Quantum (NISQ) era. Devices in this category are limited by a small number of qubits, high error rates, short coherence times and susceptibility to external noise. These factors severely limit the complexity and depth of quantum circuits that can be reliably executed, which in turn restricts the size and complexity of molecular systems that can be accurately simulated.[23]

Another significant challenge lies in the development and scalability of quantum algorithms suitable for pharmaceutical applications. While algorithms such as the Variational Quantum Eigensolver (VQE) and Quantum Approximate Optimization Algorithm (QAOA) have shown promise for modelling small molecules and solving optimization problems, they often require substantial classical pre- and post-processing and may struggle with convergence when applied to large, biologically relevant systems. Efficient encoding of molecular Hamiltonians, reduction of quantum gate counts and mitigation of algorithmic noise are ongoing areas of research aimed at improving the practical utility of these algorithms.[24,25]

Furthermore, integration of quantum computing into existing pharmaceutical R&D pipelines presents practical hurdles. Most drug discovery workflows are heavily reliant on validated classical computational infrastructure and require seamless interoperability with quantum systems. Bridging the gap between quantum outputs and classical tools used for visualization, statistical analysis and decision-making remains a work in progress.

Additionally, there is a lack of standardized frameworks and benchmarking protocols for evaluating quantum advantage in real-world drug discovery tasks, making it difficult for pharmaceutical stakeholders to assess the return on investment in quantum technologies.

Talent scarcity further hinders progress, as the interdisciplinary demands of quantum computing, which include quantum physics, computer science, computational chemistry and pharmacology, present a significant learning curve and make it challenging to develop a skilled workforce. There is a pressing need for educational initiatives, cross-disciplinary training and collaborative platforms that can cultivate a workforce capable of translating quantum innovations into pharmaceutical applications.

Lastly, regulatory and validation concerns must be addressed. Drug development is governed by stringent regulations and requires transparent, reproducible and interpretable methodologies. Quantum algorithms, particularly those that involve probabilistic outputs or opaque QML models, may pose challenges in meeting regulatory standards set by agencies such as the FDA or EMA.[26]

In summary, while the theoretical benefits of quantum computing in pharmaceutical modelling are compelling, significant hurdles related to hardware limitations, algorithmic scalability, workflow integration, talent development and regulatory compliance must be overcome. Addressing these barriers will be essential to realizing the full potential of quantum technologies in drug discovery and development.

Prospects and Roadmap for Quantum Integration in Drug Development

The integration of quantum computing into drug development holds extraordinary promise, yet realizing its full potential will require a well-orchestrated roadmap that addresses both technological and institutional dimensions. In the near term, the hybridization of quantum and classical computing systems is expected to dominate the landscape. These hybrid models combine the processing power of classical systems with the quantum advantage for specific tasks, such as molecular energy calculations, conformational sampling or quantum-enhanced feature selection. This symbiotic approach will allow pharmaceutical companies to incrementally adopt quantum tools without overhauling their existing infrastructure.

The next developmental milestone involves increasing the scale and accuracy of quantum simulations. As quantum hardware matures, with advancements in qubit coherence, error correction and gate fidelity, it will become feasible to simulate entire drug molecules and protein-ligand complexes at unprecedented levels of detail. Quantum processors capable of handling thousands of logical qubits will be necessary to transition from proof-of-concept models to production-level pharmaceutical workflows. These advancements are anticipated within the next decade, especially with sustained investment from both public and private sectors.[27]

Concurrently, algorithmic innovation will play a critical role. The development of scalable quantum algorithms tailored specifically for medicinal chemistry, protein folding, pharmacokinetic modelling and virtual screening will streamline drug development pipelines. Customizing algorithms to fit pharmaceutical use cases, such as simulating multi-target binding or metabolic pathways, will be instrumental in overcoming the limitations of generic quantum models.[28]

On the institutional front, the creation of collaborative consortia and industry standards will be essential. Initiatives such as the Quantum Economic Development Consortium (QED-C), the Pistoia Alliance and cross-sector research hubs are already laying the groundwork for standardized platforms, benchmarking protocols and interoperable toolchains. These bodies will also foster the development of educational curricula and certification programs to cultivate a skilled workforce proficient in both quantum science and pharmaceutical applications.[29]

Moreover, regulatory frameworks must evolve in parallel. Agencies like the FDA, EMA and ICH will need to establish guidelines for the validation, reproducibility and interpretability of quantum-assisted models used in drug development. Ensuring that quantum-derived predictions are robust, transparent and clinically relevant will be essential for regulatory approval and industry trust.

Long-term, the goal is to achieve end-to-end quantum-enabled drug development. This vision includes AI-assisted quantum generative design of lead compounds, quantum-enhanced simulations of ADMET profiles and real-time feedback loops for compound optimization. Cloud-based quantum platforms will democratize access, enabling smaller biotech firms and academic labs to harness the power of quantum computing without large capital investment.[29]

In essence, the roadmap for quantum integration in drug development is a multi-stage journey. It begins with hybrid systems and early adoption, progresses through hardware and algorithmic maturity and culminates in fully quantum-driven pharmaceutical innovation. With coordinated effort across research, industry, education and regulation, quantum computing is poised to redefine the future of drug discovery and development.

Ethical, Economic and Societal Implications

The transformative power of quantum computing in pharmaceutical modelling also raises critical ethical, economic and societal implications that warrant careful attention. From an economic standpoint, the integration of quantum computing could dramatically reduce R&D timelines and costs by accelerating lead optimization and minimizing experimental trial-and-error. However, the upfront investment in quantum infrastructure, including hardware, talent and training, remains substantial. This could widen the gap between resource-rich multinational pharmaceutical companies and smaller, underfunded biotech

firms or academic institutions, potentially leading to disparities in innovation access and competitiveness.

Ethically, the use of Quantum Machine Learning (QML) introduces concerns about data integrity, transparency and fairness. Quantum models often function as "black boxes," making it difficult to interpret decision-making processes or validate outcomes.[30] This lack of interpretability could pose challenges when models are used to inform clinical or regulatory decisions. Furthermore, biased training datasets may amplify existing inequalities in drug efficacy across different populations, raising concerns about equitable access to quantum-designed medicines.[31]

Societal implications are equally significant. As quantum drug discovery tools become more widespread, there is a risk that access to life-saving therapies designed through such advanced platforms could become disproportionately available to wealthier nations and communities. Bridging the global digital and technological divide is crucial to ensure that the benefits of quantum breakthroughs are equitably distributed. Efforts must be made to create inclusive frameworks that democratize access to quantum platforms, promote global collaboration and support policy-making aimed at responsible technological stewardship.[32]

In sum, while quantum computing offers vast benefits for pharmaceutical science, it must be pursued with a balanced focus on ethical transparency, equitable access and global responsibility.

Future Research Directions

As the field of quantum computing continues to evolve, several research avenues stand out as critical for its successful integration into pharmaceutical modelling. First, significant improvements are needed in the co-design of quantum hardware and software. Optimizing quantum architectures specifically for molecular simulations, such as designing qubit connectivity and coherence suited for pharmacological tasks, will be pivotal for performance scalability.[33]

Standardization of Quantum Machine Learning (QML) frameworks in drug development is another important goal. Currently, there is a lack of unified protocols for model training, validation and benchmarking.[34] Establishing common standards will not only improve reproducibility but also foster collaboration across institutions and regulatory bodies. This will also aid in developing interpretable QML models that meet the strict validation requirements of drug regulatory authorities.[35]

A forward-looking roadmap should also include strategies for real-time clinical integration of quantum outputs. This involves creating robust pipelines that can translate quantum-derived molecular predictions into actionable insights for clinicians and researchers. Developing tools for real-time compound optimization, adaptive clinical trial modelling and personalized medicine are promising frontiers.[35]

Moreover, interdisciplinary collaboration will be vital. Integrating quantum physicists, chemists, biologists, data scientists and regulatory experts into cohesive research teams will ensure holistic progress. Academic programs and industrial training modules must be expanded to cultivate the next generation of professionals equipped with both quantum and pharmaceutical competencies.

Collectively, these research directions represent a comprehensive strategy to transition quantum computing from experimental exploration to an indispensable tool in mainstream drug development.

Conclusion

Quantum computing represents a transformative frontier in pharmaceutical research, offering capabilities that can significantly elevate the precision, efficiency and scope of drug discovery and development. By overcoming the limitations of classical computational methods, quantum systems provide a fundamentally more accurate approach to simulating molecular interactions, predicting pharmacological properties and optimizing lead compounds. The integration of quantum algorithms with machine learning and classical simulations has already shown promise in enhancing molecular docking, ADMET predictions and virtual screening outcomes.

While the field is still evolving, the pace of innovation in quantum hardware, algorithm development and cross-industry collaboration indicates a clear trajectory toward practical applications. Collaborative initiatives between technology providers and pharmaceutical companies are setting the stage for early-stage adoption, while academic research continues to push the theoretical boundaries of what quantum computing can achieve in biological systems.

Nonetheless, translating quantum advances into clinical realities requires addressing substantial challenges, including hardware scalability, algorithm reliability, workforce training and regulatory validation. With sustained investment, institutional alignment and a commitment to interdisciplinary education, quantum computing is poised not only to complement but eventually redefine conventional drug discovery paradigms.

In conclusion, quantum computing stands as a promising catalyst for the next generation of drug modelling, capable of unlocking solutions for diseases previously deemed intractable. Its translational potential lies in its ability to deliver novel therapeutics faster, more accurately and with a deeper understanding of molecular complexity than ever before.

References

1. Amin SA, Gayen S, Das S, Jha T. Other modeling approaches: Pharmacophore mapping, molecular docking, and molecular dynamic simulation studies. In:

Modeling Inhibitors of Matrix Metalloproteinases. CRC Press; 2023. page 54–86.
2. Hirvensalo M. Quantum computing. Springer Science & Business Media; 2013.
3. Pal S, Bhattacharya M, Dash S, Lee SS, Chakraborty C. Future potential of quantum computing and simulations in biological science. Mol Biotechnol 2024;66(9):2201–18.
4. Mustafa H, Morapakula SN, Jain P, Ganguly S. Variational quantum algorithms for chemical simulation and drug discovery. In: 2022 International Conference on Trends in Quantum Computing and Emerging Business Technologies (TQCEBT). IEEE; 2022. page 1–8.
5. Grinstein JD. SandboxAQ Speeds Up AI Drug Discovery Simulations by Acquiring Good Chemistry: This acquisition will enhance the Alphabet spin-off's existing computational chemistry and simulation capabilities. GEN Edge 2024;6(1):33–5.
6. Nussinov R, Zhang M, Liu Y, Jang H. AlphaFold, artificial intelligence (AI), and allostery. J Phys Chem B 2022;126(34):6372–83.
7. Callison A, Chancellor N. Hybrid quantum-classical algorithms in the noisy intermediate-scale quantum era and beyond. Phys Rev A (Coll Park) 2022;106(1):010101.
8. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules 2020;25(6):1375.
9. Kesh M, Ghosh A, Biswas D. Molecular Modeling and Drug Design. Computational Methods for Rational Drug Design 2025;1–24.
10. Kubař T, Elstner M, Cui Q. Hybrid quantum mechanical/molecular mechanical methods for studying energy transduction in biomolecular machines. Annu Rev Biophys 2023;52(1):525–51.
11. Pal S, Bhattacharya M, Dash S, Lee SS, Chakraborty C. Future potential of quantum computing and simulations in biological science. Mol Biotechnol 2024;66(9):2201–18.
12. Khurana S, Nene M, Nene MJ. Quantum machine learning: unraveling a new paradigm in computational intelligence. Quantum 2024;74(1).
13. Haidar M, Rančić MJ, Ayral T, Maday Y, Piquemal J. Open source variational quantum eigensolver extension of the quantum learning machine for quantum chemistry. Wiley Interdiscip Rev Comput Mol Sci 2023;13(5):e1664.
14. Sadybekov A V, Katritch V. Computational approaches streamlining drug discovery. Nature 2023;616(7958):673–85.
15. Ganguly S, Liang X, Makris D. Hybrid classical-quantum generative algorithms for financial modelling and prediction. In: 2025 International Conference on Intelligent Control, Computing and Communications (IC3). IEEE; 2025. page 1366–76.
16. Sandeep S, Gupta V, Keenan T. Utilizing Quantum Biological Techniques on a Rigetti QPU for Improved Protein Binding Simulation. bioRxiv 2020;2020–3.
17. Callaway E. What's next for the AI protein-folding revolution. Nature 2022;604(7905):234–8.

18. Micklus A, Muntner S. Biopharma dealmaking in 2018. Nat Rev Drug Discov 2019;18(2):93–4.
19. Kumar G, Yadav S, Mukherjee A, Hassija V, Guizani M. Recent advances in quantum computing for drug discovery and development. IEEE Access 2024;
20. Belaloui NE, Tounsi A, Khamadja RA, Louamri MM, Benslama A, Neira DEB, et al. Ground State Energy Estimation on Current Quantum Hardware Through The Variational Quantum Eigensolver: A Comprehensive Study. arXiv preprint arXiv:241202606 2024;
21. Martinelli DD. Generative machine learning for de novo drug discovery: A systematic review. Comput Biol Med 2022;145:105403.
22. Ramírez JGC. Advanced quantum algorithms for big data clustering and high-dimensional classification. Journal of Advanced Computing Systems 2024;4(6).
23. Domingo L, Carlo G, Borondo F. Optimal quantum reservoir computing for the noisy intermediate-scale quantum era. Phys Rev E 2022;106(4):L043301.
24. Blekos K, Brand D, Ceschini A, Chou CH, Li RH, Pandya K, et al. A review on quantum approximate optimization algorithm and its variants. Phys Rep 2024;1068:1–66.
25. Tilly J, Chen H, Cao S, Picozzi D, Setia K, Li Y, et al. The variational quantum eigensolver: a review of methods and best practices. Phys Rep 2022;986:1–128.
26. Vasanthakumar GU, Singh M. 3 Quantum machine learning in healthcare: diagnostics and drug discovery. Quantum Machine Learning: Quantum Algorithms and Neural Networks 2024;39.
27. Pei Z. Computer-aided drug discovery: From traditional simulation methods to language models and quantum computing. Cell Rep Phys Sci 2024;5(12).
28. Ouma RBO, Ngari SM, Kibet JK. A review of the current trends in computational approaches in drug design and metabolism. Discover Public Health 2024;21(1):108.
29. Parker E. Promoting Strong International Collaboration in Quantum Technology Research and Development. Rand Corporation; 2023;56-67.
30. Hassija V, Chamola V, Mahapatra A, Singal A, Goel D, Huang K, et al. Interpreting black-box models: a review on explainable artificial intelligence. Cognit Comput 2024;16(1):45–74.
31. Bibi MJ, Kavitha V, Krishnapriya V, Gowri K, Manoj S. An Outlook on Universal Quantum Computers. Quantum Computing and Artificial Intelligence: The Industry Use Cases 2025;261–90.
32. Kop M, Aboy M, De Jong E, Gasser U, Minssen T, Cohen IG, et al. Towards responsible quantum technology: Safeguarding, engaging and advancing quantum R&D. UC L Sci & Tech J 2024;15:63.
33. Kumar G, Yadav S, Mukherjee A, Hassija V, Guizani M. Recent advances in quantum computing for drug discovery and development. IEEE Access 2024;24.
34. Avramouli M, Savvas IK, Vasilaki A, Garani G. Unlocking the potential of quantum machine learning to advance drug discovery. Electronics (Basel) 2023;12(11):2402.

35. Terranova N, Renard D, Shahin MH, Menon S, Cao Y, Hop CECA, et al. Artificial intelligence for quantitative modeling in drug discovery and development: an innovation and quality consortium perspective on use cases and best practices. Clin Pharmacol Ther 2024;115(4):658–72.